Blue Trust Inc. Grows Position in Exelixis, Inc. $EXEL

Blue Trust Inc. increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 27.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,556 shares of the biotechnology company’s stock after buying an additional 3,580 shares during the quarter. Blue Trust Inc.’s holdings in Exelixis were worth $730,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of EXEL. Nuveen LLC purchased a new position in shares of Exelixis in the 1st quarter valued at approximately $123,310,000. AQR Capital Management LLC raised its holdings in Exelixis by 73.8% during the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after purchasing an additional 2,926,884 shares during the last quarter. Invesco Ltd. raised its holdings in Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the last quarter. Jupiter Asset Management Ltd. raised its holdings in Exelixis by 233.4% during the first quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company’s stock worth $51,698,000 after purchasing an additional 980,319 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Exelixis by 935.4% during the first quarter. Pacer Advisors Inc. now owns 678,067 shares of the biotechnology company’s stock worth $25,034,000 after purchasing an additional 612,577 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Down 1.1%

Shares of NASDAQ:EXEL opened at $38.15 on Friday. The business has a fifty day simple moving average of $38.63 and a 200-day simple moving average of $39.93. Exelixis, Inc. has a 52 week low of $25.76 and a 52 week high of $49.62. The company has a market cap of $10.27 billion, a P/E ratio of 18.34, a P/E/G ratio of 0.79 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the previous year, the business earned $0.84 earnings per share. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EXEL shares. Wall Street Zen raised Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Barclays initiated coverage on Exelixis in a report on Wednesday, September 17th. They issued an “equal weight” rating and a $40.00 price target for the company. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Wednesday. Royal Bank Of Canada cut their price target on Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Tuesday, July 29th. Finally, Morgan Stanley boosted their price target on Exelixis from $46.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 17th. Fifteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.